University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital San Francisco
Search Site | Find a Doctor

John Park, M.D.

Oncologist and breast cancer specialist

Dr. John W. Park is an oncologist who specializes in breast cancer treatment and research. In his laboratory, Park works to develop novel technologies to study and treat cancer. His research includes new forms of immunotherapy such as antibodies, immunoliposomes and vaccines targeted against cancer cells. He also conducts clinical trials to evaluate new technologies and treatments for cancer patients. Park was also a visiting scientist at Genentech, Inc. where he performed research on Her2/Neu, a receptor protein on breast cancer cells, and Herceptin, a new treatment that acts as an antibody to Her2Neu. Park joined the UCSF Medical Center in 1992 as an assistant professor in the Department of Medicine.


Carol Franc Buck Breast Care Center
1600 Divisadero St., Second Floor
San Francisco, CA 94115
Phone: (415) 353-7070
Surgery Fax: (415) 353-7050
Oncology Fax: (415) 353-7692

Hours: Monday to Friday
8 a.m. – 5 p.m.

Conditions & Treatments

More about John Park


Stanford University 1986


UCLA, Internal Medicine 1989


UCSF, Hematology 1992
UCSF, Medical Oncology 1992

Selected Research and Publications

  1. Magbanua MJ, Wolf DM, Yau C, Davis SE, Crothers J, Au A, Haqq CM, Livasy C, Rugo HS. Serial expression analysis of breast tumors during neoadjuvant chemotherapy reveals changes in cell cycle and immune pathways associated with recurrence and response. Breast Cancer Res. 2015; 17(1):73.
  2. Kelley RK, Magbanua MJ, Butler TM, Collisson EA, Hwang J, Sidiropoulos N, Evason K, McWhirter RM, Hameed B, Wayne EM, Yao FY, Venook AP, Park JW. Circulating tumor cells in hepatocellular carcinoma: a pilot study of detection, enumeration, and next-generation sequencing in cases and controls. BMC Cancer. 2015; 15(1):206.
  3. DeMichele A, Yee D, Berry DA, Albain KS, Benz CC, Boughey J, Buxton M, Chia SK, Chien AJ, Chui SY, Clark A, Edmiston K, Elias A, Forero-Torres A, Haddad TC, Haley B, Haluska P, Hylton NM, Isaacs C, Kaplan H, Korde LA, Leyland-Jones B, Liu MC, Melisko M, Minton SE, Moulder S, Nanda R, Olopade OI, Paoloni M, Park JW, Parker BA, Perlmutter J, Petricoin E, Rugo HS, Symmans WF, Tripathy D, van 't Veer LJ, Viscusi RK, Wallace A, Wolf D, Yau C, Esserman LJ. The Neoadjuvant Model is Still the Future for Drug Development in Breast Cancer. Clin Cancer Res. 2015 Feb 24.
  4. Magbanua MJ, Carey LA, DeLuca A, Hwang J, Scott JH, Rimawi MF, Mayer EL, Marcom PK, Liu MC, Esteva FJ, Park JW, Rugo HS. Circulating tumor cell analysis in metastatic triple-negative breast cancers. Clin Cancer Res. 2015 Mar 1; 21(5):1098-105.
  5. Lang JE, Scott JH, Wolf DM, Novak P, Punj V, Magbanua MJ, Zhu W, Mineyev N, Haqq CM, Crothers JR, Esserman LJ, Tripathy D, van 't Veer L, Park JW. Expression profiling of circulating tumor cells in metastatic breast cancer. Breast Cancer Res Treat. 2015 Jan; 149(1):121-31.
  6. Magbanua MJ, Park JW. Advances in genomic characterization of circulating tumor cells. Cancer Metastasis Rev. 2014 Sep; 33(2-3):757-69.
  7. Paszek MJ, DuFort CC, Rossier O, Bainer R, Mouw JK, Godula K, Hudak JE, Lakins JN, Wijekoon AC, Cassereau L, Rubashkin MG, Magbanua MJ, Thorn KS, Davidson MW, Rugo HS, Park JW, Hammer DA, Giannone G, Bertozzi CR, Weaver VM. The cancer glycocalyx mechanically primes integrin-mediated growth and survival. Nature. 2014 Jul 17; 511(7509):319-25.
  8. Chien AJ, Munster PN, Melisko ME, Rugo HS, Park JW, Goga A, Auerback G, Khanafshar E, Ordovas K, Koch KM, Moasser MM. Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer. J Clin Oncol. 2014 May 10; 32(14):1472-9.
  9. Noble CO, Krauze MT, Drummond DC, Forsayeth J, Hayes ME, Beyer J, Hadaczek P, Berger MS, Kirpotin DB, Bankiewicz KS, Park JW. Pharmacokinetics, tumor accumulation and antitumor activity of nanoliposomal irinotecan following systemic treatment of intracranial tumors. Nanomedicine (Lond). 2014 Jul; 9(14):2099-108.
  10. Magbanua MJ, Melisko M, Roy R, Sosa EV, Hauranieh L, Kablanian A, Eisenbud LE, Ryazantsev A, Au A, Scott JH, Park JW. Molecular profiling of tumor cells in cerebrospinal fluid and matched primary tumors from metastatic breast cancer patients with leptomeningeal carcinomatosis. Cancer Res. 2013 Dec 1; 73(23):7134-43.
  11. Magbanua MJ, Park JW. Isolation of circulating tumor cells by immunomagnetic enrichment and fluorescence-activated cell sorting (IE/FACS) for molecular profiling. Methods. 2013 Dec 1; 64(2):114-8.
  12. Weng KC, Hashizume R, Noble CO, Serwer LP, Drummond DC, Kirpotin DB, Kuwabara AM, Chao LX, Chen FF, James CD, Park JW. Convection-enhanced delivery of targeted quantum dot-immunoliposome hybrid nanoparticles to intracranial brain tumor models. Nanomedicine (Lond). 2013 Dec; 8(12):1913-25.
  13. DeMichele A, Berry DA, Zujewski J, Hunsberger S, Rubinstein L, Tomaszewski JE, Kelloff G, Perlmutter J, Buxton M, Lyandres J, Albain KS, Benz C, Chien AJ, Haluska P, Leyland-Jones B, Liu MC, Munster P, Olopade O, Park JW, Parker BA, Pusztai L, Tripathy D, Rugo H, Yee D, Esserman L. Developing safety criteria for introducing new agents into neoadjuvant trials. Clin Cancer Res. 2013 Jun 1; 19(11):2817-23.
  14. Magbanua MJ, Sosa EV, Roy R, Eisenbud LE, Scott JH, Olshen A, Pinkel D, Rugo HS, Park JW. Genomic profiling of isolated circulating tumor cells from metastatic breast cancer patients. Cancer Res. 2013 Jan 1; 73(1):30-40.
  15. Petrillo LA, Wolf DM, Kapoun AM, Wang NJ, Barczak A, Xiao Y, Korkaya H, Baehner F, Lewicki J, Wicha M, Park JW, Spellman PT, Gray JW, van't Veer L, Esserman LJ. Xenografts faithfully recapitulate breast cancer-specific gene expression patterns of parent primary breast tumors. Breast Cancer Res Treat. 2012 Oct; 135(3):913-22.
  16. Magbanua MJ, Sosa EV, Scott JH, Simko J, Collins C, Pinkel D, Ryan CJ, Park JW. Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer. BMC Cancer. 2012; 12:78.
  17. Gedda L, Fondell A, Lundqvist H, Park JW, Edwards K. Experimental radionuclide therapy of HER2-expressing xenografts using two-step targeting nuclisome particles. J Nucl Med. 2012 Mar; 53(3):480-7.
  18. Rugo HS, Chien AJ, Franco SX, Stopeck AT, Glencer A, Lahiri S, Arbushites MC, Scott J, Park JW, Hudis C, Nulsen B, Dickler MN. A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat. 2012 Jul; 134(1):13-20.
  19. Heiser LM, Sadanandam A, Kuo WL, Benz SC, Goldstein TC, Ng S, Gibb WJ, Wang NJ, Ziyad S, Tong F, Bayani N, Hu Z, Billig JI, Dueregger A, Lewis S, Jakkula L, Korkola JE, Durinck S, Pepin F, Guan Y, Purdom E, Neuvial P, Bengtsson H, Wood KW, Smith PG, Vassilev LT, Hennessy BT, Greshock J, Bachman KE, Hardwicke MA, Park JW, Marton LJ, Wolf DM, Collisson EA, Neve RM, Mills GB, Speed TP, Feiler HS, Wooster RF, Haussler D, Stuart JM, Gray JW, Spellman PT. Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc Natl Acad Sci U S A. 2012 Feb 21; 109(8):2724-9.
  20. Serwer LP, Noble CO, Michaud K, Drummond DC, Kirpotin DB, Ozawa T, Prados MD, Park JW, James CD. Investigation of intravenous delivery of nanoliposomal topotecan for activity against orthotopic glioblastoma xenografts. Neuro Oncol. 2011 Dec; 13(12):1288-95.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.